Skip to content
ContentLora

    Tip: press / anywhere to search.

    concept

    DNA synthesis order screening

    Also known as nucleic acid synthesis screening, gene synthesis screening, sequence screening

    DNA synthesis order screening is the practice of checking sequence orders and customer identity before synthetic DNA is shipped, and it is the main governance layer over the synthesis supply chain.[1][2] The United States ties federal life-sciences funding to buying from compliant providers under a framework released on 29 April 2024, which agencies were ordered in May 2025 to revise or replace; no replacement had been published as of October 2026.[3][4]

    Editor reviewedStrict sourcingUpdated Synthetic biologyTech policyScience
    Key facts

    What it is and why it exists

    Synthetic DNA is ordered digitally and delivered physically, so the provider is the point where a sequence request becomes a material. Screening means two checks at that point: comparing the ordered sequence against sequences of concern, and verifying that the customer is a legitimate institution. The US framework applies the same logic to benchtop synthesis devices as to central providers, because a device in a laboratory performs the same function as a shipment.[1]

    US guidance for providers and users of synthetic nucleic acids dates back to 2010 and has been updated several times since.[5]

    The current US framework

    The White House Office of Science and Technology Policy released its Framework for Nucleic Acid Synthesis Screening on 29 April 2024.[3] Its mechanism is procurement rather than prohibition: as a condition of receiving US federal life-sciences research funding, institutions must buy synthetic nucleic acids, and benchtop devices capable of making them, only from providers and manufacturers that comply with the framework.[1]

    That design means the framework reaches internationally through the purchasing choices of federally funded laboratories, but does not by itself cover work outside federal funding.[1]

    Status as of October 2026

    The executive order “Improving the Safety and Security of Biological Research”, issued on 5 May 2025, directed federal departments and agencies to revise or replace the 2024 framework. As of October 2026 the responsible US government pages still say they will be updated once the revised framework is available.[4] In other words, the operative rules are the 2024 ones while a replacement is pending.

    Tooling

    Screening capacity, not just policy, determines coverage. The International Biosecurity and Biosafety Initiative for Science distributes the Common Mechanism, a free, open-source screening tool that providers can run locally without sending order data to IBBIS.[2] The effort traces to a 2019 convening by the Nuclear Threat Initiative and the World Economic Forum, and named adopters include Dynegene and the Shenzhen Institute of Advanced Technology.[6]

    Where implementation falls short

    A peer-reviewed analysis published on 28 October 2025 identified three obstacles to effective sequence-level governance: ambiguous definitions of sequences of concern, fragmented regulatory triggers that overlap without assigning responsibility, and underdeveloped institutional capacity.[7] On capacity it reports that most institutional biosafety offices run with fewer than three full-time professional staff while also handling committee reviews, incident response and training.[8] On the provider side it cites interview research finding substantial variation in screening sensitivity, treatment of short oligonucleotides, and monitoring and evaluation.[9]

    The same analysis notes that no confirmed malicious incidents involving synthetic nucleic acids have been documented to date, and proposes seven reforms including functional risk tiering, federal infrastructure investment, institutional certification pathways and pragmatic global harmonisation.[10][11]

    Who it binds

    Screening sits on the commercial layer described in how DNA synthesis works, so it applies to large providers such as Twist Bioscience and, through the device clause, to benchtop synthesis instruments.[1] The policy arguments about scope and enforcement are set out in this field’s analysis page on the screening debate, which weighs funding-linked rules against statutory options and international harmonisation.[11]

    Questions readers ask

    What is DNA synthesis screening?

    Providers check what sequence an order corresponds to and whether the customer is legitimate before shipping synthetic DNA; the US framework covers both commercial providers and benchtop synthesis devices.[1]

    Is screening legally required in the United States?

    It is attached to funding rather than imposed as a general law. The 2024 framework makes compliant purchasing a condition of receiving US federal life-sciences research funding.[1][3]

    Has the framework changed?

    A 5 May 2025 executive order directed agencies to revise or replace it, and as of October 2026 the responsible US government page says it will be updated once the revised framework is available.[4]

    How do smaller providers screen orders?

    One option is the Common Mechanism, a free open-source tool distributed by IBBIS that runs locally so order data is not sent to a third party.[2]

    Does screening work consistently?

    Not yet. A 2025 peer-reviewed analysis cites substantial variation between providers in screening sensitivity, treatment of short oligonucleotides, and monitoring and evaluation.[9]

    Sources

    Each numbered claim is a statement we checked against the sources listed with it. Status shows how well established it is.

    1. [1]

      The 2024 framework makes it a condition of US federal life-sciences research funding that synthetic nucleic acids, and benchtop devices that can make them, are bought only from providers and manufacturers that comply with the framework. confirmedas of 2026-10-10

    2. [2]

      The International Biosecurity and Biosafety Initiative for Science distributes the Common Mechanism, a free open-source screening tool that DNA and RNA providers can run locally without sending order data to IBBIS. confirmedas of 2026-10-10

    3. [3]

      The White House Office of Science and Technology Policy released its Framework for Nucleic Acid Synthesis Screening on 29 April 2024. confirmedas of 2026-10-10

    4. [4]

      Under the executive order "Improving the Safety and Security of Biological Research" of 5 May 2025, federal agencies are to revise or replace the 2024 framework, and as of October 2026 the responsible US government page says it will be updated once the revised framework is available. confirmedas of 2026-10-10

    5. [5]

      US screening guidance for providers and users of synthetic nucleic acids was first issued in 2010 and updated in later versions, including a 2023 update. confirmedas of 2026-10-10

    6. [6]

      The Common Mechanism began as a 2019 effort convened by the Nuclear Threat Initiative and the World Economic Forum, and named adopters include Dynegene and the Shenzhen Institute of Advanced Technology. reportedas of 2026-10-10

    7. [7]

      A 2025 peer-reviewed analysis identified three obstacles to effective sequence-level governance: ambiguous definitions of sequences of concern, fragmented regulatory triggers, and underdeveloped institutional capacity. confirmedas of 2025-10-28

    8. [8]

      The same analysis reports that most institutional biosafety offices operate with fewer than three full-time professional staff while handling committee reviews, incident response and training. confirmedas of 2025-10-28

    9. [9]

      The analysis cites interview research finding substantial variation between synthesis providers in screening sensitivity, treatment of short oligonucleotides, and monitoring and evaluation. confirmedas of 2025-10-28

    10. [10]

      As of October 2025 the peer-reviewed literature reported no confirmed malicious incidents involving synthetic nucleic acids. confirmedas of 2025-10-28

    11. [11]

      The 2025 analysis proposes seven reforms, including risk tiering by function, federal infrastructure investment, institutional certification pathways and pragmatic global harmonisation. confirmedas of 2025-10-28

    Revision history (2)
    1. Page created.
    2. Refresh: replaced paraphrased excerpts with verbatim quotes from the HHS and OSTP framework pages, the 2025 peer-reviewed analysis and the IBBIS Common Mechanism page. No change to the claims themselves.

    Created Oct 10, 2026. Last reviewed by an editor on Oct 10, 2026. Next scheduled review: Jan 10, 2027.

    Cite this page

    "DNA synthesis order screening." ContentLora, updated Oct 10, 2026. https://contentlora.com/wiki/dna-synthesis-screening

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.

    Keep exploring

    Connections
    Twist Bioscience Applies toEnzymatic DNA synth… Applies to benchtop devic…
    ☰ Contents